

COPYRIGHT LICENSE AGREEMENT

1 INFORMATION FOR YOUR MANUSCRIPT

Name of Journal: World Journal of Diabetes

Manuscript NO.: 88728

Column: Basic Study

Title: Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

All Author List: Gu-Lao Zhang, Yuan Liu, Yan-Feng Liu, Xian-Tao Huang, Yu Tao, Zhen-Huan Chen and Heng-Li Lai

Corresponding Author: Zhen-Huan Chen, MD, Attending Doctor, Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Aiguo Road, Donghu District, Nanchang 330000, Jiangxi Province, China. 350696233@qq.com

Received Date: 2023-10-08

2 COPYRIGHT LICENSE AGREEMENT

World Journal of Diabetes is a high-quality, online, open-access, single-blind peer-reviewed journal published by the Baishideng Publishing Group (*Baishideng*). After consultation by the authors and *Baishideng*, the authors agree that if this manuscript is finally accepted for publication, the Copyright License Agreement will become effective immediately. Application for copyright license agreement will be made by written declaration of and attestation to the following:

2.1 ©The Author(s): The copyright on any open access article in a journal published by *Baishideng* is retained by the author(s).



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

2.2 Author(s) grant Baishideng permission to publish the article: Author(s) grant Baishideng license to publish the article and identify itself as the original publisher.

2.3 Author(s) grant copyright permission: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

<http://creativecommons.org/licenses/by-nc/4.0/>

2.4 Simultaneous submission statement: Author(s) certify that the manuscript is not simultaneously being considered by other journals nor is already published elsewhere.

2.5 Academic misconduct statement: Author(s) certify that the manuscript has no redundancy, plagiarism, data fabrication, or falsification.

2.6 Conflict of interest statement: Author(s) certify that there is no conflict of interest related to the manuscript. If any potential conflict-of-interest exists, author(s) certify that it is fully disclosed.

2.7 Ethics statement: Author(s) certify that all experiments involving animals and human subjects were designed and performed in compliance with the relevant laws regarding humane care and use of subjects.

2.8 Referenced figures and tables authorization statement: Author(s) certify that the manuscript's content is original, with all information from other sources appropriately referenced, and that specific permission has been granted in writing by any existing copyright holders prior to publication and is clearly cited and available.

2.9 Author(s) grant Baishideng permission to use the published articles exclusively: Author(s) grant exclusive copyright ownership to Baishideng for all formats of the



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

manuscript, including print and electronic formats, English and non-English language formats, and subsequent editions such as Erratum, in addition to all rights for (1) granting permission to republish or reprint the materials in whole or in part, with or without a fee, (2) printing copies for free distribution or for sale, and (3) republishing the materials in a compendium or in any other format.

2.10 Author(s) grant *Baishideng* permission to publish manuscript-related documents:

Author(s) grant permission to *Baishideng* to publish manuscript-related documents (*e.g.*, peer review report, answers to reviewers, CrossCheck report, signed copyright license agreement, etc.) at the same time that the manuscript is published online.

2.11 Author(s) declare that the language of the manuscript is correct and free of language errors: Author(s) certify that the manuscript contains no errors in grammar, syntax, spelling, punctuation, or logic.

2.12 Author(s) declare that the figure(s) and table(s) are quoted correctly: Author(s) certify that all figures and tables have been correctly placed and clearly identified, and meet the journal's standards of high-resolution quality.

2.13 Author(s) declare that the references are cited correctly: Author(s) certify that the references are numbered according to their order of appearance in the main text of the manuscript.

3 PUBLISHING FEE STATEMENT

'Manuscript source' includes invited manuscripts and unsolicited manuscripts. The article processing charge (APC) is waived for invited manuscripts. The APC must be paid for any unsolicited manuscript. The APC is payable to *Baishideng* by the author(s) or research sponsor(s). All *Baishideng* publications' APC standards can be found at: <https://www.wjgnet.com/bpg/gerinfo/242>



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

<https://www.wjgnet.com>

4 SIGNATURES OF ALL AUTHORS

This declaration must be signed by all authors. The manuscript will be rejected immediately if we find the declaration was not signed by authors themselves. The signature list for all authors is as follows:

1 Name:	Gu-Lao Zhang <u>Gu-Lao Zhang</u>	Date:	2023-12-06 <u>2023-12-06</u>
2 Name:	Yuan Liu <u>Yuan Liu</u>	Date:	2023-12-06 <u>2023-12-07</u>
3 Name:	Yan-Feng Liu <u>Yan-Feng Liu</u>	Date:	2023-12-07 <u>2023.12.7</u>
4 Name:	Xian-Tao Huang <u>Xian-Tao Huang</u>	Date:	2023-12-07 <u>2023.12.7</u>
5 Name:	Yu Tao <u>Yu Tao</u>	Date:	2023-12-09 <u>2023.12-9</u>
6 Name:	Zhen-Huan Chen <u>Zhen-Huan Chen</u>	Date:	2023-12-06 <u>2023.12.06</u>
7 Name:	Heng-Li Lai <u>Hengli Lai</u>	Date:	<u>2023-12-30</u>

Dear Editors,

In the previous version of our manuscript (**Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome** NO.: 88728), Dr. Chen Zhenhuan and Dr. Lai Hengli were the co-corresponding authors, and Dr. Chen Zhenhuan was ranking first. Because Dr. Lai Hengli made important contributions in the revision process, all authors agreed that Lai Hengli should be the first corresponding author. The current order of authors is: Gulao Zhang, Yuan Liu, Yanfeng Liu, Xiantao Huang, Yu Tao, Zhenhuan Chen, Hengli Lai. We hope you will approve our request. Thank you very much.

Your sincerely,

Zhenhuan Chen, Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Aiguo Road, Donghu District, Nanchang, Jiangxi 330000, China, Email address 350696233@qq.com

Gulao Zhang	Gulao Zhang	Date	2024-1-24
Yuan Liu	yuan Liu	Date	2024-01-24
Yanfeng Liu	Yanfeng Liu	Date	2024.1.24
Xiantao Huang	Xiantao Huang	Date	2024.1.24
Yu Tao	Yu Tao	Date	2024.1.24
Zhenhuan Chen	Zhenhuan Chen	Date	2024.1.24
Hengli Lai	Hengli Lai	Date	2024.1.24